Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[[Cyclosporin forever?].

J F Borel1

  • 1Recherche pré-clinique, Laboratoires Sandoz, Bâle (Suisse).

Nephrologie
|January 1, 1987
PubMed
Summary

Cyclosporine effectively controls graft rejection, but lower doses, combined with other drugs like azathioprine or steroids, are recommended. Its mechanism involves altering graft antigenicity and suppressing immune responses, making it valuable in transplantation and immunology research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunomodulation: particular perspectives.

Transplantation proceedings·1999
Same author

The Florence dinner speech, 15th February, 1998.

Transplantation proceedings·1999
Same author

Long-term survival of hamster islet xenografts in mice under short-course treatment with nondepleting versus depleting anti-CD4 monoclonal antibodies.

Xenotransplantation·1998
Same author

Requirement of CD4 cells for induction and maintenance of unresponsiveness in islet xenografted mice.

Xenotransplantation·1998
Same author

Effects of immunopharmacological compounds in the Lyme arthritis model using normal and SCID mice.

International journal of immunopharmacology·1998
Same author

Induction of unresponsiveness to islet xenografts by a short-course treatment by anti-CD4 nondepleting monoclonal antibody.

Transplantation proceedings·1998

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Graft rejection remains a significant challenge in organ transplantation.
  • Cyclosporine is a key immunosuppressant used to prevent rejection.
  • Optimizing cyclosporine dosage is crucial to balance efficacy and toxicity.

Purpose of the Study:

  • To review the role of cyclosporine in controlling graft rejection.
  • To explore strategies for reducing cyclosporine dosage.
  • To elucidate the immunomodulatory mechanisms of cyclosporine.

Main Methods:

  • Review of existing literature on cyclosporine in transplantation.
  • Analysis of combined immunosuppressive therapies (cyclosporine with azathioprine/steroids).
  • Examination of cyclosporine's effects on graft antigenicity and immune cell function.

Main Results:

  • Cyclosporine dosage reduction is achievable with combination therapy.
  • Cyclosporine impacts graft antigenicity, notably reducing MHC class II expression.
  • Cyclosporine profoundly modifies lymphokine secretion, inhibiting DTH responses and activating suppressor cells.

Conclusions:

  • Cyclosporine is vital for managing graft rejection.
  • Combination therapy allows for reduced cyclosporine dosage, potentially minimizing side effects.
  • Cyclosporine serves as an important research tool for understanding immune responses in transplantation and immunology.

Related Experiment Videos